KR20120097481A - 사람 혈청 알부민(HSA)의 변이체와 컨쥬게이션된 αvβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도 - Google Patents

사람 혈청 알부민(HSA)의 변이체와 컨쥬게이션된 αvβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도 Download PDF

Info

Publication number
KR20120097481A
KR20120097481A KR1020127004303A KR20127004303A KR20120097481A KR 20120097481 A KR20120097481 A KR 20120097481A KR 1020127004303 A KR1020127004303 A KR 1020127004303A KR 20127004303 A KR20127004303 A KR 20127004303A KR 20120097481 A KR20120097481 A KR 20120097481A
Authority
KR
South Korea
Prior art keywords
polypeptide
glu
ala
lys
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127004303A
Other languages
English (en)
Korean (ko)
Inventor
워에이-절 촹
원-메이 푸
Original Assignee
내셔날 쳉쿵 유니버시티
디씨비-유에스에이 엘엘씨
내셔널 타이완 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔날 쳉쿵 유니버시티, 디씨비-유에스에이 엘엘씨, 내셔널 타이완 유니버시티 filed Critical 내셔날 쳉쿵 유니버시티
Publication of KR20120097481A publication Critical patent/KR20120097481A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020127004303A 2009-07-20 2010-07-19 사람 혈청 알부민(HSA)의 변이체와 컨쥬게이션된 αvβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도 Withdrawn KR20120097481A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22694509P 2009-07-20 2009-07-20
US61/226,945 2009-07-20

Publications (1)

Publication Number Publication Date
KR20120097481A true KR20120097481A (ko) 2012-09-04

Family

ID=43465728

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127004303A Withdrawn KR20120097481A (ko) 2009-07-20 2010-07-19 사람 혈청 알부민(HSA)의 변이체와 컨쥬게이션된 αvβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도

Country Status (14)

Country Link
US (1) US20110015130A1 (https=)
EP (1) EP2456454A4 (https=)
JP (1) JP2012533631A (https=)
KR (1) KR20120097481A (https=)
CN (1) CN102470156A (https=)
AR (1) AR077764A1 (https=)
AU (1) AU2010276453A1 (https=)
CA (1) CA2768360A1 (https=)
IL (1) IL217424A0 (https=)
MX (1) MX2012000895A (https=)
NZ (1) NZ597580A (https=)
RU (1) RU2547592C2 (https=)
TW (1) TWI557224B (https=)
WO (1) WO2011011315A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170042366A (ko) * 2014-08-22 2017-04-18 내셔널 청쿵 유니버시티 디스인테그린 변이체 및 이의 약학적 용도
KR20200013101A (ko) * 2015-06-28 2020-02-05 올제네시스 바이오테라퓨틱스 아이엔씨. 혈관신생 억제용 융합 단백질

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
US8357652B2 (en) * 2009-11-20 2013-01-22 Academia Sinica Anti-tumor fibrillar human serum albumin methods and compositions
NZ600544A (en) * 2009-12-23 2014-06-27 Univ Nat Cheng Kung Compositions and methods for the treatment of angiogenesis-related eye diseases
KR20130020765A (ko) 2010-02-16 2013-02-28 메디뮨 엘엘씨 Hsa-관련 조성물 및 사용방법
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
AU2016304794B2 (en) 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
EA034582B1 (ru) * 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
CN114126648A (zh) 2019-05-31 2022-03-01 Alx肿瘤生物技术公司 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法
CN121243368A (zh) 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
US20240148839A1 (en) * 2021-03-16 2024-05-09 Km Biologics Co., Ltd. Modified human serum albumin-thioredoxin fusion body
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2026022392A1 (en) * 2024-07-26 2026-01-29 Ospedale San Raffaele S.R.L. Peptide and conjugates thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU5939890A (en) * 1989-06-07 1991-01-07 Genentech Inc. Platelet aggregation inhibitors and related molecules
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
WO2003042354A2 (en) * 2001-09-04 2003-05-22 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
WO2003040384A1 (en) * 2001-11-05 2003-05-15 Board Of Regents, The University Of Texas System Recombinant antibodies for the detection and neutralization of anthrax toxin
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
JP2005529166A (ja) * 2002-06-07 2005-09-29 ウィスコンシン アルムニ リサーチ ファウンデーション ペプチドカップリングのための試薬の化学合成
EP1730187A1 (en) * 2004-03-18 2006-12-13 The University Court Of The University Of Glasgow Immunosuppressive cytokine
WO2008056961A1 (en) * 2006-11-10 2008-05-15 Boryung Pharmaceutical Co., Ltd A novel fusion protein, cell lines expressing the same and preparation method thereof
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
NZ600544A (en) * 2009-12-23 2014-06-27 Univ Nat Cheng Kung Compositions and methods for the treatment of angiogenesis-related eye diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170042366A (ko) * 2014-08-22 2017-04-18 내셔널 청쿵 유니버시티 디스인테그린 변이체 및 이의 약학적 용도
KR20200013101A (ko) * 2015-06-28 2020-02-05 올제네시스 바이오테라퓨틱스 아이엔씨. 혈관신생 억제용 융합 단백질

Also Published As

Publication number Publication date
IL217424A0 (en) 2012-02-29
EP2456454A4 (en) 2013-03-20
US20110015130A1 (en) 2011-01-20
RU2547592C2 (ru) 2015-04-10
JP2012533631A (ja) 2012-12-27
TWI557224B (zh) 2016-11-11
MX2012000895A (es) 2012-06-01
AU2010276453A1 (en) 2012-02-09
NZ597580A (en) 2013-11-29
CA2768360A1 (en) 2011-01-27
AR077764A1 (es) 2011-09-21
EP2456454A1 (en) 2012-05-30
WO2011011315A1 (en) 2011-01-27
TW201107471A (en) 2011-03-01
CN102470156A (zh) 2012-05-23
RU2012105915A (ru) 2013-08-27

Similar Documents

Publication Publication Date Title
KR20120097481A (ko) 사람 혈청 알부민(HSA)의 변이체와 컨쥬게이션된 αvβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도
CN101677537B (zh) 解联蛋白变体及其药学用途
EP1135413A2 (en) Proteins that bind angiogenesis-inhibiting proteins, compoisitions and methods of use thereof
EP2859898B1 (en) Therapeutic agent and test method for diseases associated with activation of neutrophils
KR20130004568A (ko) 항-전이성 요법에서 axl 신호전달의 저해
US10870684B2 (en) Disintegrin variants and pharmaceutical uses thereof
CN112979764B (zh) 特异结合人cd47分子的多肽及其用途
JP2002335972A (ja) インスリン受容体関連受容体結合蛋白質及びその利用
HK1136160B (en) Disintegrin variants and pharmaceutical uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid